Abstract
Negative regulator of reactive oxygen species (NRROS) is a leucine-rich repeat protein expressed by microglia and perivascular macrophages. To date, 9 individuals have been reported with biallelic NRROS variants. Here, we report one individual with a severe neurodegenerative phenotype in which exome sequencing identified 2 novel variants in NRROS, a missense variant (c.185T>C, p.Leu62Pro) and a premature stop codon (c.310C>T, p.Gln104Ter). Pathological examination revealed both extensive grey and white matter involvement, dystrophic calcifications, and infiltration of foamy macrophages. This is the first reported case of NRROS variants with a mitochondrial ultrastructure abnormality noted on electron microscopy analysis of post-mortem tissue.
This is a preview of subscription content, access via your institution.


Data availability
The data supporting this study are included within the report.
References
Noubade R, Wong K, Ota N, Rutz S, Eidenschenk C, Valdez PA et al (2014) NRROS negatively regulates reactive oxygen species during host defence and autoimmunity. Nature 509(7499):235–239. https://doi.org/10.1038/nature13152
Qin Y, Garrison BS, Ma W, Wang R, Jiang A, Li J et al (2018) A Milieu Molecule for TGF-beta required for microglia function in the nervous system. Cell. 174(1):156–71 e16. https://doi.org/10.1016/j.cell.2018.05.027
Liu J, Zhang Z, Chai L, Che Y, Min S, Yang R (2013) Identification and characterization of a unique leucine-rich repeat protein (LRRC33) that inhibits Toll-like receptor-mediated NF-kappaB activation. Biochem Biophys Res Commun 434(1):28–34. https://doi.org/10.1016/j.bbrc.2013.03.071
Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G et al (2014) Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 17(1):131–143. https://doi.org/10.1038/nn.3599
Smith C, McColl BW, Patir A, Barrington J, Armishaw J, Clarke A et al (2020) Biallelic mutations in NRROS cause an early onset lethal microgliopathy. Acta Neuropathol 139(5):947–951. https://doi.org/10.1007/s00401-020-02137-7
Dong X, Tan NB, Howell KB, Barresi S, Freeman JL, Vecchio D et al (2020) Bi-allelic LoF NRROS variants impairing active TGF-beta1 delivery cause a severe infantile-onset neurodegenerative condition with intracranial calcification. Am J Hum Genet 106(4):559–569. https://doi.org/10.1016/j.ajhg.2020.02.014
Kumar V (2019) Toll-like receptors in the pathogenesis of neuroinflammation. J Neuroimmunol 332:16–30. https://doi.org/10.1016/j.jneuroim.2019.03.012
Surace MJ, Block ML (2012) Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell Mol Life Sci 69(14):2409–2427. https://doi.org/10.1007/s00018-012-1015-4
Subhramanyam CS, Wang C, Hu Q, Dheen ST (2019) Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol 94:112–120. https://doi.org/10.1016/j.semcdb.2019.05.004
Terrone G, Balosso S, Pauletti A, Ravizza T, Vezzani A (2020) Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology 167:107742. https://doi.org/10.1016/j.neuropharm.2019.107742
Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J et al (2007) Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 81(4):713–725. https://doi.org/10.1086/521373
Kotlarz D, Marquardt B, Baroy T, Lee WS, Konnikova L, Hollizeck S et al (2018) Human TGF-beta1 deficiency causes severe inflammatory bowel disease and encephalopathy. Nat Genet 50(3):344–348. https://doi.org/10.1038/s41588-018-0063-6
Brionne TC, Tesseur I, Masliah E, Wyss-Coray T (2003) Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 40(6):1133–1145. https://doi.org/10.1016/s0896-6273(03)00766-9
Swerdlow RH (2009) Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals (Basel). 2(3):150–67. https://doi.org/10.3390/ph2030150
Cole NB, Daniels MP, Levine RL, Kim G (2010) Oxidative stress causes reversible changes in mitochondrial permeability and structure. Exp Gerontol 45(7–8):596–602. https://doi.org/10.1016/j.exger.2010.01.016
Acknowledgements
The authors wish to thank the patient and her family for their participation in this study. The authors also wish to acknowledge the McGill University and Genome Quebec Innovation Center.
Funding
This research was funded by research grants from the Canadian Institutes for Health Research (project grant 426534 and 201610PJT- 377869). This research was enabled in part by support provided by Compute Canada (www.computecanada.ca). JM is supported by Healthy Brains, Healthy Lives (HBHL) at McGill University. AD is funded by CIHR, Fondation du Grand Defi Pierre Lavoie and HBHL. AV is funded by the Kamens Chair in Translational Neurotherapeutics.
G. Bernard has received the Clinical Research Scholar Junior 1 award from the Fonds de Recherche du Québec – Santé (FRQS) (2012–2016), the New Investigator Salary Award from the Canadian Institutes of Health Research (2017–2022) and the Clinical Research Scholar Senior award from the FRQS.
Author information
Authors and Affiliations
Contributions
JM — Designed and conceptualized the study; acquisition of data; analysis and interpretation of data; drafted and revised the manuscript for intellectual content. AD — Acquisition of data; analysis and interpretation of data; revised the manuscript for intellectual content. CP — Acquisition of data and revised the manuscript for intellectual content. NB — Acquisition of data and revised the manuscript for intellectual content. AV — Acquisition of data and revised the manuscript for intellectual content. IT — Acquisition of data, analysis and interpretation of data; revised the manuscript for intellectual content. SA — Acquisition of data; analysis and interpretation of data; drafted and revised the manuscript for intellectual content. GB — Designed and conceptualized the study; acquisition of data; analysis and interpretation of data; drafted and revised the manuscript for intellectual content; study supervision.
Corresponding author
Ethics declarations
Ethics approval
Written informed consent from the legal representatives of the subject was obtained and the study was approved by the research ethics boards of the Montreal Children’s Hospital and the McGill University Health Center (11–105-PED, 2019–4972).
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Macintosh, J., Derksen, A., Poulin, C. et al. Novel biallelic variants in NRROS associated with a lethal microgliopathy, brain calcifications, and neurodegeneration. Neurogenetics 23, 151–156 (2022). https://doi.org/10.1007/s10048-022-00683-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10048-022-00683-8